• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

DEVELOPMENT OF EGFR ANTISENSE GENE THERAPY AGAINST MALIGNANT GLIOMAS USING A RECOMBINANT RETRO-VIRUS VECTOR

Research Project

Project/Area Number 06454421
Research Category

Grant-in-Aid for General Scientific Research (B)

Allocation TypeSingle-year Grants
Research Field Cerebral neurosurgery
Research InstitutionKYOTO PREFECTURAL UNIVERSITY OF MEDICINE

Principal Investigator

UEDA Satoshi  KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,PROFESSOR, 医学部, 教授 (40094411)

Co-Investigator(Kenkyū-buntansha) MORITA Noriyuki  KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,ASSISTANT PROFESSOR, 医学部, 助手 (50239662)
KAWATA Mituhiro  KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,PROFESSOR, 医学部, 教授 (60112512)
NAKAGAWA Yoshio  KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,ASSISTANT PROFESSOR, 医学部, 講師 (00188913)
SUGAWA Noriaki  KYOTO PREFECTURAL UNIVERSITY OF MEDICINE,MEDICAL SCHOOL,ASSISTANT PROFESSOR, 医学部, 助手 (50244596)
Project Period (FY) 1994 – 1995
Project Status Completed (Fiscal Year 1995)
Budget Amount *help
¥7,300,000 (Direct Cost: ¥7,300,000)
Fiscal Year 1995: ¥1,900,000 (Direct Cost: ¥1,900,000)
Fiscal Year 1994: ¥5,400,000 (Direct Cost: ¥5,400,000)
Keywordsmalignant glioma / EGFR antisense gene therapy / retro-virus / aberrant EGFR / malignant afioma / EGFR ontisense gene therapy / レトロウイルス / 異常EGFR / antisense gene therapy / EGFR / retrovirus
Research Abstract

Epidermal growth factor receptor (EGFR) plays an important role in the progression of malignancy in gliomas. We studied the growth inhibition of the malignant glioma cell lines using an antisense EGFR oligonucleotide (normal phosphodister oligonucleotide) enveloped with Lipofectin^R (BRL) and we could have a good result. This time, we succeeded to develop the recombinant retro-virus vector expressiog EGFR antisense oligonucleotide, and we could inhibit the growth of the malignant glioma cell line using this retro-virus vector.
We analyzed structure of EGFR in 80 gliomas, and found that 40% of human malignant gliomas in vivo expressed aberrant EGFR.Furthermore, we have found two kinds of new aberrant EGFR.

Report

(3 results)
  • 1995 Annual Research Report   Final Research Report Summary
  • 1994 Annual Research Report
  • Research Products

    (7 results)

All Other

All Publications (7 results)

  • [Publications] 須川典亮,上田聖: "アンチセンスDNAを用いた遺伝子治療" Clinical neuroscience. 12(6). 684-686 (1994)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Noriaki Sugawa,Yoshio Nakagawa,et al: "Brain Tumor Research and Therapy" Sprimger-Uelag Tokyo, 4 (1995)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Noriaki Sugawa, Satoshi Ueda: "Gene therapy using antisense DNA" Clinical Neuroscience. 12(6). 684-686 (1994)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] Noriaki Sugawa, Yoshio Nakagawa, Satoshi Ueda: "Point mutations of Epidermal Growth Factor Receptor Transcripts in Primary Human Malignant Gliomas" Brain Tumor Research and Therapy. Springer-Verlag, Tokyo. 233-236 (1995)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1995 Final Research Report Summary
  • [Publications] 須川典亮,上田聖: "アンチセンスDNAを用いた遺伝子治療" Clinical neuroscience. 12(6). 684-686 (1994)

    • Related Report
      1995 Annual Research Report
  • [Publications] Noriaki Sugawa,et al: "Brain Tomar Research and Therapy" Springer-Verlag Tokyo, 4 (1995)

    • Related Report
      1995 Annual Research Report
  • [Publications] 須川,典亮,上田聖: "アンチセンスDNAを用いた遺伝子治療" Clinical Neuroscience. 12(6). 96-98 (1994)

    • Related Report
      1994 Annual Research Report

URL: 

Published: 1994-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi